Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Osterborg

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Haematologica|January 19, 2007
Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systemsAmir Osman Abdalla, Lotta Hansson, Ingrid Eriksson, et al.
Blood|April 9, 2004
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomasGunilla Enblad, Hans Hagberg, Martin Erlanson, et al.
Blood|April 30, 2005
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cellsLina Y Dimberg, Anna I Dimberg, Karolina Ivarsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignanciesParviz Kokhaei, Amir Osman Abdalla, Lotta Hansson, et al.
Investigational New Drugs|December 21, 2007
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemiaMarkus Jensen, Andreas Engert, Florian Weissinger, et al.
Medical Oncology (Northwood, London, England)|September 18, 2007
Erythropoietin therapy and cancer related anaemia: updated Swedish recommendationsJane Ahlqvist-Rastad, Maria Albertsson, Jonas Bergh, et al.
Blood|January 25, 2003
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndromeJeanette Lundin, Hans Hagberg, Roland Repp, et al.
Cancer Immunology, Immunotherapy : CII|May 20, 2008
Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal studyFariba Mozaffari, Christina Lindemalm, Aniruddha Choudhury, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 15, 2007
Immune response, depression and fatigue in relation to support intervention in mammary cancer patientsChristina Lindemalm, Fariba Mozaffari, Aniruddha Choudhury, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Haematologica|January 19, 2007
Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systemsAmir Osman Abdalla, Lotta Hansson, Ingrid Eriksson, et al.
Blood|April 9, 2004
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomasGunilla Enblad, Hans Hagberg, Martin Erlanson, et al.
Blood|April 30, 2005
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cellsLina Y Dimberg, Anna I Dimberg, Karolina Ivarsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignanciesParviz Kokhaei, Amir Osman Abdalla, Lotta Hansson, et al.
Investigational New Drugs|December 21, 2007
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemiaMarkus Jensen, Andreas Engert, Florian Weissinger, et al.
Medical Oncology (Northwood, London, England)|September 18, 2007
Erythropoietin therapy and cancer related anaemia: updated Swedish recommendationsJane Ahlqvist-Rastad, Maria Albertsson, Jonas Bergh, et al.
Blood|January 25, 2003
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndromeJeanette Lundin, Hans Hagberg, Roland Repp, et al.
Cancer Immunology, Immunotherapy : CII|May 20, 2008
Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal studyFariba Mozaffari, Christina Lindemalm, Aniruddha Choudhury, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 15, 2007
Immune response, depression and fatigue in relation to support intervention in mammary cancer patientsChristina Lindemalm, Fariba Mozaffari, Aniruddha Choudhury, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
Pageof 8